Agilent Technologies (A)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$131.13+0.41%
Close 2026-07-07 · 1-day change
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading A? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track A free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAgilent's revenue growth for fiscal year 2026 has to keep compounding to justify the price. Revenue grew 10% year over year, and the last quarter beat expectations by 5.7%. It trades at 22.5× P/E versus a peer median of 35.4×, indicating that the price reflects less growth than forecasted. If Agilent cuts guidance on the next call, that could negatively impact its stock, as the Street tends to lower estimates in such cases, with a miss probability of 17%. Peer multiples imply a price about 4% above where it trades.
Trailing returns as of 2026-07-07. A is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering A (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for A in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. Current price $131.13. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Advances: Revenue growth for fiscal year 2026
Earnings beat and guidance raise support revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $131.13
The last 12 months of price, then the range of analyst 12-month targets from today’s $131.13.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Revenue growth for fiscal year 2026
Upgrade indicates strong revenue growth potential.
Advances: Revenue growth for fiscal year 2026
New center and acquisition enhance growth potential in diagnostics.